A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
This study has been completed.
Study NCT00034619
Information provided by Eli Lilly and Company
First Received: May 1, 2002
Last Updated: July 18, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
